A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors

Phase 1 Not yet recruiting 128 enrolled TJ Biopharma Co., Ltd.

NaSequentialOpen-labelTreatment

Summary

The goal of this clinical trial is to evaluate the safety and tolerability of TJ037130 in participants with advanced or metastatic solid tumors, and to determine the Potential Optimal Biological Dose (POBD) of TJ037130 for subsequent investigations.

Timeline

Start: 2026-08-21
Primary completion: 2028-06-30
Completion: 2028-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TJ037130	Unknown	0.75 mg/kg	—
Subject	TJ037130	Unknown	2 mg/kg	—
Subject	TJ037130	Unknown	5 mg/kg	—
Subject	TJ037130	Unknown	10 mg/kg	—
Subject	TJ037130	Unknown	18 mg/kg	—

A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors

Summary

Timeline

Drugs

Indications